For example, the results of a phase Ib clinical trial (NCT02179918) find that in advanced solid tumor patients treated with Utomilumab (a human monoclonal antibody agonist targeting the T cell co-stimulatory receptor CD137) combined with pembrolizumab, higher levels of activated memory/effector peripheral blood CD8 T cells are observed, leading to profound and durable anti-tumor activity and high safety [379]. This evidence concerns the gene CD8A and neoplasm.